Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Registration Number
- NCT01345084
- Locations
- 🇧🇷
Hospital Amaral Carvalho, Jau, São Paulo, Brazil
🇧🇷Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil
🇧🇷Hospital Erasto Gaetner, Curitiba, Paraná, Brazil
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Peking University
- Target Recruit Count
- 70
- Registration Number
- NCT01336049
- Locations
- 🇨🇳
Xiaodong Zhang, Beijing, Beijing, China
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Registration Number
- NCT01301612
- Locations
- 🇧🇷
Centro de Pesquisas Clínicas da Fundação Amaral Carvalho, Jau, São Paulo, Brazil
🇧🇷ICESP, São Paulo, Brazil
🇧🇷Centro de Pesquisa Clínica da Liga Norte Riograndense contra o Câncer, Natal, Rio Grande do Norte, Brazil
A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 104
- Registration Number
- NCT01249352
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil
🇧🇷Santa Casa de Misericórdia de BH, Belo Horizonte, MG, Brazil
🇧🇷Hospital Geral de Bonsucesso, Rio de Janeiro, RJ, Brazil
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT01232374
- Locations
- 🇨🇳
Cancer Center of Sun Yat-sen, Guangzhou, Guangdong, China
🇨🇳Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01180166
- Locations
- 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT01074021
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The Affiliated Renji Hosptial of ShanghaiJiao Tong University, Shanghai, China
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 710
- Registration Number
- NCT00957086
- Locations
- 🇰🇷
National Cancer Center Korea, Gyeonggi-do, Korea, Republic of
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
🇦🇺Flinders Medical Centre, Bedford Park, Australia
Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT00950417
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Interventions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT00910117
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.